Modeling the Adenosine Receptors:  Comparison of the Binding Domains of A2A Agonists and Antagonists

A three-dimensional model of the human A2A adenosine receptor (AR) and its docked ligands was built by homology to rhodopsin and validated with site-directed mutagenesis and the synthesis of chemically complementary agonists. Different binding modes of A2AAR antagonists and agonists were compared by...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Journal of medicinal chemistry 2003-11, Vol.46 (23), p.4847-4859
Hauptverfasser: Kim, Soo-Kyung, Gao, Zhan-Guo, Van Rompaey, Philippe, Gross, Ariel S, Chen, Aishe, Van Calenbergh, Serge, Jacobson, Kenneth A
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 4859
container_issue 23
container_start_page 4847
container_title Journal of medicinal chemistry
container_volume 46
creator Kim, Soo-Kyung
Gao, Zhan-Guo
Van Rompaey, Philippe
Gross, Ariel S
Chen, Aishe
Van Calenbergh, Serge
Jacobson, Kenneth A
description A three-dimensional model of the human A2A adenosine receptor (AR) and its docked ligands was built by homology to rhodopsin and validated with site-directed mutagenesis and the synthesis of chemically complementary agonists. Different binding modes of A2AAR antagonists and agonists were compared by using the FlexiDock automated docking procedure, with manual adjustment. Putative binding regions for the 9H-purine ring in agonist NECA 3 and the 1H-[1,2,4]triazolo[1,5-c]quinazoline ring in antagonist CGS15943 1 overlapped, and the exocyclic amino groups of each were H-bonded to the side chain of N6.55. For bound agonist, H-bonds formed between the ribose 3‘- and 5‘-substituents and the hydrophilic amino acids T3.36, S7.42, and H7.43, and the terminal methyl group of the 5‘-uronamide interacted with the hydrophobic side chain of F6.44. Formation of the agonist complex destabilized the ground-state structure of the A2AAR, which was stabilized through a network of H-bonding and hydrophobic interactions in the transmembrane helical domain (TM) regions, facilitating a conformational change upon activation. Both flexibility of the ribose moiety, required for the movement of TM6, and its H-bonding to the receptor were important for agonism. Two sets of interhelical H-bonds involved residues conserved among ARs but not in rhodopsin:  (1) E131.39 and H2787.43 and (2) D522.50, with the highly conserved amino acids N2807.45 and S2817.46, and N2847.49 with S913.39. Most of the amino acid residues lining the putative binding site(s) were conserved among the four AR subtypes. The A2AAR/3 complex showed a preference for an intermediate conformation about the glycosidic bond, unlike in the A3AR/3 complex, which featured an anti-conformation. Hydrophilic amino acids of TMs 3 and 7 (ribose-binding region) were replaced with anionic residues for enhanced binding to amine-derivatized agonists. We identified new neoceptor (T88D)-neoligand pairs that were consistent with the model.
doi_str_mv 10.1021/jm0300431
format Article
fullrecord <record><control><sourceid>istex_pubme</sourceid><recordid>TN_cdi_pubmed_primary_14584936</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>ark_67375_TPS_XBMKS082_0</sourcerecordid><originalsourceid>FETCH-LOGICAL-a220t-c6e2102afd5de534b504708d20462390cea4a6e3ff307645cfd62c843a4c044a3</originalsourceid><addsrcrecordid>eNpFkU1PwkAQhjdGI4ge_AOmF4_V6e62FG8FPyNEI5h42wz7gUW623RLojev_k1_iUVQTpOZeebNvHkJOY7gLAIanc8LYACcRTukHcUUQp4C3yVtAEpDmlDWIgfezwGARZTtk1bE45T3WNImZuSUXuR2FtSvOsiUts7nVgdPWuqydpW_-P78CgauKLHKvbOBM79kP7dqdXXpCsytX40zmgXZzNnc1z5Aq4LM1rjpD8mewYXXR5vaIc_XV5PBbTh8uLkbZMMQKYU6lImmjSM0KlY6ZnwaA-9CqijwxkUPpEaOiWbGMOgmPJZGJVSmnCGXwDmyDjlZ65bLaaGVKKu8wOpD_BlugNMNgF7iwlRoZe63XEwbDHoNF6655nv9_r_H6k0kXdaNxeRxLF76o_sxpFTAVhelF3O3rGxjU0QgVgGJ_4DYD3nMfmQ</addsrcrecordid><sourcetype>Index Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>Modeling the Adenosine Receptors:  Comparison of the Binding Domains of A2A Agonists and Antagonists</title><source>MEDLINE</source><source>American Chemical Society Journals</source><creator>Kim, Soo-Kyung ; Gao, Zhan-Guo ; Van Rompaey, Philippe ; Gross, Ariel S ; Chen, Aishe ; Van Calenbergh, Serge ; Jacobson, Kenneth A</creator><creatorcontrib>Kim, Soo-Kyung ; Gao, Zhan-Guo ; Van Rompaey, Philippe ; Gross, Ariel S ; Chen, Aishe ; Van Calenbergh, Serge ; Jacobson, Kenneth A</creatorcontrib><description>A three-dimensional model of the human A2A adenosine receptor (AR) and its docked ligands was built by homology to rhodopsin and validated with site-directed mutagenesis and the synthesis of chemically complementary agonists. Different binding modes of A2AAR antagonists and agonists were compared by using the FlexiDock automated docking procedure, with manual adjustment. Putative binding regions for the 9H-purine ring in agonist NECA 3 and the 1H-[1,2,4]triazolo[1,5-c]quinazoline ring in antagonist CGS15943 1 overlapped, and the exocyclic amino groups of each were H-bonded to the side chain of N6.55. For bound agonist, H-bonds formed between the ribose 3‘- and 5‘-substituents and the hydrophilic amino acids T3.36, S7.42, and H7.43, and the terminal methyl group of the 5‘-uronamide interacted with the hydrophobic side chain of F6.44. Formation of the agonist complex destabilized the ground-state structure of the A2AAR, which was stabilized through a network of H-bonding and hydrophobic interactions in the transmembrane helical domain (TM) regions, facilitating a conformational change upon activation. Both flexibility of the ribose moiety, required for the movement of TM6, and its H-bonding to the receptor were important for agonism. Two sets of interhelical H-bonds involved residues conserved among ARs but not in rhodopsin:  (1) E131.39 and H2787.43 and (2) D522.50, with the highly conserved amino acids N2807.45 and S2817.46, and N2847.49 with S913.39. Most of the amino acid residues lining the putative binding site(s) were conserved among the four AR subtypes. The A2AAR/3 complex showed a preference for an intermediate conformation about the glycosidic bond, unlike in the A3AR/3 complex, which featured an anti-conformation. Hydrophilic amino acids of TMs 3 and 7 (ribose-binding region) were replaced with anionic residues for enhanced binding to amine-derivatized agonists. We identified new neoceptor (T88D)-neoligand pairs that were consistent with the model.</description><identifier>ISSN: 0022-2623</identifier><identifier>EISSN: 1520-4804</identifier><identifier>DOI: 10.1021/jm0300431</identifier><identifier>PMID: 14584936</identifier><identifier>CODEN: JMCMAR</identifier><language>eng</language><publisher>Washington, DC: American Chemical Society</publisher><subject>Adenosine A2 Receptor Agonists ; Adenosine A2 Receptor Antagonists ; Adenosine-5'-(N-ethylcarboxamide) - chemistry ; Adenosine-5'-(N-ethylcarboxamide) - pharmacology ; Animals ; Binding Sites ; Biological and medical sciences ; COS Cells ; Humans ; Hydrogen Bonding ; Hydrophobic and Hydrophilic Interactions ; Ligands ; Medical sciences ; Models, Molecular ; Mutagenesis, Site-Directed ; Neuropharmacology ; Neurotransmitters. Neurotransmission. Receptors ; Peptidergic system (neuropeptide, opioid peptide, opiates...). Adenosinergic and purinergic systems ; Pharmacology. Drug treatments ; Protein Conformation ; Quinazolines - chemistry ; Quinazolines - pharmacology ; Radioligand Assay ; Receptors, Adenosine A2 - genetics ; Triazoles - chemistry ; Triazoles - pharmacology</subject><ispartof>Journal of medicinal chemistry, 2003-11, Vol.46 (23), p.4847-4859</ispartof><rights>Copyright © 2003 American Chemical Society</rights><rights>2004 INIST-CNRS</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://pubs.acs.org/doi/pdf/10.1021/jm0300431$$EPDF$$P50$$Gacs$$H</linktopdf><linktohtml>$$Uhttps://pubs.acs.org/doi/10.1021/jm0300431$$EHTML$$P50$$Gacs$$H</linktohtml><link.rule.ids>314,780,784,27076,27924,27925,56738,56788</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&amp;idt=15249309$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/14584936$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Kim, Soo-Kyung</creatorcontrib><creatorcontrib>Gao, Zhan-Guo</creatorcontrib><creatorcontrib>Van Rompaey, Philippe</creatorcontrib><creatorcontrib>Gross, Ariel S</creatorcontrib><creatorcontrib>Chen, Aishe</creatorcontrib><creatorcontrib>Van Calenbergh, Serge</creatorcontrib><creatorcontrib>Jacobson, Kenneth A</creatorcontrib><title>Modeling the Adenosine Receptors:  Comparison of the Binding Domains of A2A Agonists and Antagonists</title><title>Journal of medicinal chemistry</title><addtitle>J. Med. Chem</addtitle><description>A three-dimensional model of the human A2A adenosine receptor (AR) and its docked ligands was built by homology to rhodopsin and validated with site-directed mutagenesis and the synthesis of chemically complementary agonists. Different binding modes of A2AAR antagonists and agonists were compared by using the FlexiDock automated docking procedure, with manual adjustment. Putative binding regions for the 9H-purine ring in agonist NECA 3 and the 1H-[1,2,4]triazolo[1,5-c]quinazoline ring in antagonist CGS15943 1 overlapped, and the exocyclic amino groups of each were H-bonded to the side chain of N6.55. For bound agonist, H-bonds formed between the ribose 3‘- and 5‘-substituents and the hydrophilic amino acids T3.36, S7.42, and H7.43, and the terminal methyl group of the 5‘-uronamide interacted with the hydrophobic side chain of F6.44. Formation of the agonist complex destabilized the ground-state structure of the A2AAR, which was stabilized through a network of H-bonding and hydrophobic interactions in the transmembrane helical domain (TM) regions, facilitating a conformational change upon activation. Both flexibility of the ribose moiety, required for the movement of TM6, and its H-bonding to the receptor were important for agonism. Two sets of interhelical H-bonds involved residues conserved among ARs but not in rhodopsin:  (1) E131.39 and H2787.43 and (2) D522.50, with the highly conserved amino acids N2807.45 and S2817.46, and N2847.49 with S913.39. Most of the amino acid residues lining the putative binding site(s) were conserved among the four AR subtypes. The A2AAR/3 complex showed a preference for an intermediate conformation about the glycosidic bond, unlike in the A3AR/3 complex, which featured an anti-conformation. Hydrophilic amino acids of TMs 3 and 7 (ribose-binding region) were replaced with anionic residues for enhanced binding to amine-derivatized agonists. We identified new neoceptor (T88D)-neoligand pairs that were consistent with the model.</description><subject>Adenosine A2 Receptor Agonists</subject><subject>Adenosine A2 Receptor Antagonists</subject><subject>Adenosine-5'-(N-ethylcarboxamide) - chemistry</subject><subject>Adenosine-5'-(N-ethylcarboxamide) - pharmacology</subject><subject>Animals</subject><subject>Binding Sites</subject><subject>Biological and medical sciences</subject><subject>COS Cells</subject><subject>Humans</subject><subject>Hydrogen Bonding</subject><subject>Hydrophobic and Hydrophilic Interactions</subject><subject>Ligands</subject><subject>Medical sciences</subject><subject>Models, Molecular</subject><subject>Mutagenesis, Site-Directed</subject><subject>Neuropharmacology</subject><subject>Neurotransmitters. Neurotransmission. Receptors</subject><subject>Peptidergic system (neuropeptide, opioid peptide, opiates...). Adenosinergic and purinergic systems</subject><subject>Pharmacology. Drug treatments</subject><subject>Protein Conformation</subject><subject>Quinazolines - chemistry</subject><subject>Quinazolines - pharmacology</subject><subject>Radioligand Assay</subject><subject>Receptors, Adenosine A2 - genetics</subject><subject>Triazoles - chemistry</subject><subject>Triazoles - pharmacology</subject><issn>0022-2623</issn><issn>1520-4804</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2003</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNpFkU1PwkAQhjdGI4ge_AOmF4_V6e62FG8FPyNEI5h42wz7gUW623RLojev_k1_iUVQTpOZeebNvHkJOY7gLAIanc8LYACcRTukHcUUQp4C3yVtAEpDmlDWIgfezwGARZTtk1bE45T3WNImZuSUXuR2FtSvOsiUts7nVgdPWuqydpW_-P78CgauKLHKvbOBM79kP7dqdXXpCsytX40zmgXZzNnc1z5Aq4LM1rjpD8mewYXXR5vaIc_XV5PBbTh8uLkbZMMQKYU6lImmjSM0KlY6ZnwaA-9CqijwxkUPpEaOiWbGMOgmPJZGJVSmnCGXwDmyDjlZ65bLaaGVKKu8wOpD_BlugNMNgF7iwlRoZe63XEwbDHoNF6655nv9_r_H6k0kXdaNxeRxLF76o_sxpFTAVhelF3O3rGxjU0QgVgGJ_4DYD3nMfmQ</recordid><startdate>20031106</startdate><enddate>20031106</enddate><creator>Kim, Soo-Kyung</creator><creator>Gao, Zhan-Guo</creator><creator>Van Rompaey, Philippe</creator><creator>Gross, Ariel S</creator><creator>Chen, Aishe</creator><creator>Van Calenbergh, Serge</creator><creator>Jacobson, Kenneth A</creator><general>American Chemical Society</general><scope>BSCLL</scope><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope></search><sort><creationdate>20031106</creationdate><title>Modeling the Adenosine Receptors:  Comparison of the Binding Domains of A2A Agonists and Antagonists</title><author>Kim, Soo-Kyung ; Gao, Zhan-Guo ; Van Rompaey, Philippe ; Gross, Ariel S ; Chen, Aishe ; Van Calenbergh, Serge ; Jacobson, Kenneth A</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-a220t-c6e2102afd5de534b504708d20462390cea4a6e3ff307645cfd62c843a4c044a3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2003</creationdate><topic>Adenosine A2 Receptor Agonists</topic><topic>Adenosine A2 Receptor Antagonists</topic><topic>Adenosine-5'-(N-ethylcarboxamide) - chemistry</topic><topic>Adenosine-5'-(N-ethylcarboxamide) - pharmacology</topic><topic>Animals</topic><topic>Binding Sites</topic><topic>Biological and medical sciences</topic><topic>COS Cells</topic><topic>Humans</topic><topic>Hydrogen Bonding</topic><topic>Hydrophobic and Hydrophilic Interactions</topic><topic>Ligands</topic><topic>Medical sciences</topic><topic>Models, Molecular</topic><topic>Mutagenesis, Site-Directed</topic><topic>Neuropharmacology</topic><topic>Neurotransmitters. Neurotransmission. Receptors</topic><topic>Peptidergic system (neuropeptide, opioid peptide, opiates...). Adenosinergic and purinergic systems</topic><topic>Pharmacology. Drug treatments</topic><topic>Protein Conformation</topic><topic>Quinazolines - chemistry</topic><topic>Quinazolines - pharmacology</topic><topic>Radioligand Assay</topic><topic>Receptors, Adenosine A2 - genetics</topic><topic>Triazoles - chemistry</topic><topic>Triazoles - pharmacology</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Kim, Soo-Kyung</creatorcontrib><creatorcontrib>Gao, Zhan-Guo</creatorcontrib><creatorcontrib>Van Rompaey, Philippe</creatorcontrib><creatorcontrib>Gross, Ariel S</creatorcontrib><creatorcontrib>Chen, Aishe</creatorcontrib><creatorcontrib>Van Calenbergh, Serge</creatorcontrib><creatorcontrib>Jacobson, Kenneth A</creatorcontrib><collection>Istex</collection><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><jtitle>Journal of medicinal chemistry</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Kim, Soo-Kyung</au><au>Gao, Zhan-Guo</au><au>Van Rompaey, Philippe</au><au>Gross, Ariel S</au><au>Chen, Aishe</au><au>Van Calenbergh, Serge</au><au>Jacobson, Kenneth A</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Modeling the Adenosine Receptors:  Comparison of the Binding Domains of A2A Agonists and Antagonists</atitle><jtitle>Journal of medicinal chemistry</jtitle><addtitle>J. Med. Chem</addtitle><date>2003-11-06</date><risdate>2003</risdate><volume>46</volume><issue>23</issue><spage>4847</spage><epage>4859</epage><pages>4847-4859</pages><issn>0022-2623</issn><eissn>1520-4804</eissn><coden>JMCMAR</coden><abstract>A three-dimensional model of the human A2A adenosine receptor (AR) and its docked ligands was built by homology to rhodopsin and validated with site-directed mutagenesis and the synthesis of chemically complementary agonists. Different binding modes of A2AAR antagonists and agonists were compared by using the FlexiDock automated docking procedure, with manual adjustment. Putative binding regions for the 9H-purine ring in agonist NECA 3 and the 1H-[1,2,4]triazolo[1,5-c]quinazoline ring in antagonist CGS15943 1 overlapped, and the exocyclic amino groups of each were H-bonded to the side chain of N6.55. For bound agonist, H-bonds formed between the ribose 3‘- and 5‘-substituents and the hydrophilic amino acids T3.36, S7.42, and H7.43, and the terminal methyl group of the 5‘-uronamide interacted with the hydrophobic side chain of F6.44. Formation of the agonist complex destabilized the ground-state structure of the A2AAR, which was stabilized through a network of H-bonding and hydrophobic interactions in the transmembrane helical domain (TM) regions, facilitating a conformational change upon activation. Both flexibility of the ribose moiety, required for the movement of TM6, and its H-bonding to the receptor were important for agonism. Two sets of interhelical H-bonds involved residues conserved among ARs but not in rhodopsin:  (1) E131.39 and H2787.43 and (2) D522.50, with the highly conserved amino acids N2807.45 and S2817.46, and N2847.49 with S913.39. Most of the amino acid residues lining the putative binding site(s) were conserved among the four AR subtypes. The A2AAR/3 complex showed a preference for an intermediate conformation about the glycosidic bond, unlike in the A3AR/3 complex, which featured an anti-conformation. Hydrophilic amino acids of TMs 3 and 7 (ribose-binding region) were replaced with anionic residues for enhanced binding to amine-derivatized agonists. We identified new neoceptor (T88D)-neoligand pairs that were consistent with the model.</abstract><cop>Washington, DC</cop><pub>American Chemical Society</pub><pmid>14584936</pmid><doi>10.1021/jm0300431</doi><tpages>13</tpages></addata></record>
fulltext fulltext
identifier ISSN: 0022-2623
ispartof Journal of medicinal chemistry, 2003-11, Vol.46 (23), p.4847-4859
issn 0022-2623
1520-4804
language eng
recordid cdi_pubmed_primary_14584936
source MEDLINE; American Chemical Society Journals
subjects Adenosine A2 Receptor Agonists
Adenosine A2 Receptor Antagonists
Adenosine-5'-(N-ethylcarboxamide) - chemistry
Adenosine-5'-(N-ethylcarboxamide) - pharmacology
Animals
Binding Sites
Biological and medical sciences
COS Cells
Humans
Hydrogen Bonding
Hydrophobic and Hydrophilic Interactions
Ligands
Medical sciences
Models, Molecular
Mutagenesis, Site-Directed
Neuropharmacology
Neurotransmitters. Neurotransmission. Receptors
Peptidergic system (neuropeptide, opioid peptide, opiates...). Adenosinergic and purinergic systems
Pharmacology. Drug treatments
Protein Conformation
Quinazolines - chemistry
Quinazolines - pharmacology
Radioligand Assay
Receptors, Adenosine A2 - genetics
Triazoles - chemistry
Triazoles - pharmacology
title Modeling the Adenosine Receptors:  Comparison of the Binding Domains of A2A Agonists and Antagonists
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-29T02%3A58%3A20IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-istex_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Modeling%20the%20Adenosine%20Receptors:%E2%80%89%20Comparison%20of%20the%20Binding%20Domains%20of%20A2A%20Agonists%20and%20Antagonists&rft.jtitle=Journal%20of%20medicinal%20chemistry&rft.au=Kim,%20Soo-Kyung&rft.date=2003-11-06&rft.volume=46&rft.issue=23&rft.spage=4847&rft.epage=4859&rft.pages=4847-4859&rft.issn=0022-2623&rft.eissn=1520-4804&rft.coden=JMCMAR&rft_id=info:doi/10.1021/jm0300431&rft_dat=%3Cistex_pubme%3Eark_67375_TPS_XBMKS082_0%3C/istex_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/14584936&rfr_iscdi=true